Structure Therapeutics

Phase A — Understand the business

Lens 1 · Company Overview

Structure Therapeutics is a clinical-stage biopharma with no approved products and no product revenue, built around one differentiated idea: use structure-based drug discovery (founder Raymond Stevens' GPCR crystallography lineage) to make oral small molecules that hit targets historically owned by injectable peptides. The whole company is a pipeline, not a P&L.

Corporate facts:

• Cayman Islands exempted company, HQ South San Francisco. Originally formed in Delaware in 2016 as ShouTi Inc., reorganized to Cayman in Feb 2019.
• Trades on Nasdaq as ADSs, where 1 ADS = 3 ordinary shares (ticker GPCR). 213,223,549 ordinary shares outstanding as of 2026-04-30 → ~71.1M ADS-equivalent.
• Large accelerated filer (not an emerging-growth / smaller-reporting company) — i.e., it is past the small-cap reporting carve-outs despite zero revenue.

The pipeline (the actual business):

Note the pipeline narrowed between filings: the FY2025 10-K lists five clinical candidates (incl. ANPA-0073); the Q1-2026 10-Q lists four — ANPA-0073 dropped from the clinical-stage list after the company "decided it was not suitable for selective weight loss".

Customers / suppliers / contract structure: There are no customers — no commercial product. customers.csv is empty (header-only). Manufacturing is fully outsourced to third-party CDMOs; the company explicitly runs an asset-light model ("eliminating the need for us to invest in our own manufacturing facilities") and is building a US + ex-China supply base for API and drug product. The only material "contract" revenue to date is a $100.0M non-dilutive upfront license fee received in Q1-2026 for a class of oral GLP-1 patents distinct from aleniglipron — see Lens 3/9.

Lens 2 · Supply Chain

For a clinical-stage drug company the "supply chain" is the CDMO + clinical-trial stack, and Structure is deliberately virtual.

Upstream → company → end:

• Discovery input: in-house structure-based drug discovery platform (cryo-EM / X-ray GPCR structures) → small-molecule candidates. This is the one piece they own.
• API + drug product: outsourced to third-party manufacturers; explicit strategy to "contract in parallel with additional suppliers in the United States and other regions outside of China" to diversify. Named CDMOs are not disclosed in the filing text reviewed — n/a — not named in filings.
• Clinical execution: trials run partly outside the US (a flagged regulatory risk — FDA may not accept foreign data; see Lens 10).
• Chokepoint: the binding constraint is not physical supply — an oral small molecule is far easier to scale than an injectable peptide (the 10-K argues exactly this: peptide injectables are "limited by fill-finish capacity and device requirements," and oral peptides like oral semaglutide by "large drug substance requirements arising from their poor bioavailability"). The chokepoint is clinical and regulatory — getting through Phase 3 and FDA before the franchise economics are taken. Manufacturing scalability is, ironically, the moat (Lens 3), not the bottleneck.

This lens stays partly generic because the filings don't name the CDMOs; flagged honestly rather than fabricated.

Lens 3 · Competitive Advantages (moats)

Three real edges, one structural disadvantage.

1 · The oral small-molecule manufacturing advantage (the durable one). The entire thesis is that oral small molecules can be manufactured at population scale and cost in a way injectable peptides (Wegovy, Zepbound) and even oral peptides (oral semaglutide) cannot. The 10-K makes the argument directly: injectable scalability is capped by fill-finish/devices; oral-peptide scalability is capped by poor bioavailability requiring huge drug-substance loads. A potent oral small molecule sidesteps both. In a market measured in tens of millions of patients, supply cost is a genuine moat — but it is a moat the entire small-molecule field shares (Lilly, Pfizer, Viking, Roche/Carmot), not a Structure-exclusive one.

2 · The discovery platform + IP estate. Structure-based GPCR drug design is the founder's life's work (Lens 9). The $100M upfront license fee in Q1-2026 — paid by a third party for a different class of Structure's oral GLP-1 patents — is hard market validation that the IP estate has standalone value beyond the lead asset. Patent families cover aleniglipron, the amylin assets (ACCG-2671/-3535), and ANPA-0073/APJ.

3 · Pipeline breadth in the right modality. Beyond GLP-1, Structure is the most advanced oral small-molecule amylin program (ACCG-2671) — amylin is the hottest mechanism in obesity after the Lilly/Novo amylin races. Optionality on a 2nd mechanism, all oral.

Bargaining power: essentially none today — pre-revenue, no product, dependent on capital markets and CDMOs. Its leverage is entirely optionality value (a partner/acquirer wanting an oral GLP-1 or oral amylin). The $100M license shows it can monetize IP without dilution, which is the closest thing to bargaining power it has.

The structural disadvantage: Structure does not own the category-defining advantage — time. Lilly's orforglipron is already approved (Lens 7/12/13). A manufacturing/IP moat is worth far less when the incumbent crossed the finish line first with a 2,000-person commercial machine behind it.

Lens 4 · Segments

Not applicable — no revenue, no segments. segments.csv is header-only. The company reports a single R&D cost center. For a +clinical name the "segment" view is the asset table (Lens 1) and the spend split:

Operating-expense split, Q1-2026 vs Q1-2025:

Spend is accelerating hard as the program moves toward Phase 3 — R&D up 55% YoY, G&A up 70% YoY (the latter is the cost of staffing up as a commercial-track large-cap-filer). This is the expected shape of a biotech approaching its most expensive trials.

---

Phase B — Measure performance (clinical-stage swap)

Lens 5 · Pipeline by Phase (replaces Earnings Result)

The asset table is the company. Programs with status, next readout, and a probability-of-success read:

Aleniglipron (GSBR-1290) — lead, oral GLP-1R agonist, obesity.

• Phase 2b ACCESS (core): placebo-adjusted mean weight loss 11.3% (27.3 lbs) at 120mg / 36 wks, statistically significant across all active arms; AE-related treatment discontinuation ~10.4% at the efficacious dose.
• Phase 2b ACCESS II (exploratory dose-finding): up to 15.3% (35.5 lbs) at 240mg and 16.3% (39 lbs) at 180mg, 36 wks.
• ACCESS OLE (open-label extension): continued weight loss with no plateau out to 44–56 weeks — up to 16.2% at 120mg / 56 wks.
• Tolerability fix: a lower 2.5mg starting titration (vs 5mg) produced zero AE-related discontinuations at initiation in OLE/Body-Composition studies — directly addressing the core-study 10.4% dropout.
• Next: Phase 3 registrational program in chronic weight management initiates Q3 2026, starting at 2.5mg, per End-of-Phase-2 FDA feedback. PoS read: moderate-to-good for the trial (the efficacy is real and dose-responsive); the risk is competitive/commercial, not primarily mechanistic.

ACCG-2671 — oral small-molecule amylin (DACRA), obesity. Phase 1 SAD ongoing (initiated Dec 2025); industry's most advanced oral small-molecule amylin. SAD initial data + MAD initiation expected Q3 2026. Caution flag: the 10-K's own preclinical disclosure says "combination therapy with semaglutide... resulted in superior weight loss compared to ACCG-2671 monotherapy" — i.e., as a monotherapy the amylin asset trailed semaglutide in preclinical models; the pitch is combination/oral-stack, not standalone dominance.

ACCG-3535 — 2nd oral amylin; Phase 1 init expected Q4 2026. LTSE-2578 — oral small molecule for IPF; early clinical, non-obesity optionality. ANPA-0073 — deprioritized (Lens 10).

Lens 7 · Catalyst Calendar + Mechanism Comps (replaces Comps)

Catalyst calendar (next 12 months):

Mechanism comps (by target, not P/E — the +clinical rule):

Valuation reference points (not a multiples table — pre-revenue): market cap ~$2.93B (2026-06-10); price ~$70–89 across June quotes. Sell-side 12-mo PT: avg ~$97–107, range $65–$140 (Guggenheim $140 high, H.C. Wainwright cut to $70 on 2026-06-11, Goldman $102, Jefferies $79). No EV/Sales, P/E, ROE — n/a, pre-revenue development-stage.

Lens 8 · Stock-Price Catalysts

What actually moves GPCR is binary clinical data and the dilution that follows it — textbook clinical-biotech tape.

• Dec 8, 2025 — ACCESS topline: stock +104% to +121% intraday on the positive Phase 2b read. The single most important value-creation event in the company's history.
• Dec 9–16, 2025 — the give-back: shares slid ~8–9%/day into the high-$50s as the company priced a ~$747.5M follow-on (closed Dec 11, net $701.5M) — profit-taking + dilution, not bad data.
• June 11, 2026 — H.C. Wainwright PT cut $100→$70 — sentiment cooling as the orforglipron-approval reality sets in and the stock sits below several targets.
• Pattern: the market reacts almost exclusively to (a) aleniglipron efficacy/safety prints and (b) capital raises. There is no revenue, no guidance, no macro sensitivity beyond risk-appetite for unprofitable biotech and the read-through from Lilly/Novo/Viking obesity news. Expect outsized moves on the Q3 2026 Phase 3 start, the ADA dataset, and the first ACCG-2671 human data.

---

Phase C — Judge people & books

Lens 9 · Management

CEO & founder: Raymond C. Stevens, Ph.D. — one of the strongest scientific-founder track records in the sector.

• Track record (quantified, this is the bull pillar on people): pioneer of structure-based drug discovery; founded Receptos → developed Zeposia (S1PR1 GPCR agonist, approved 2020 MS / 2021 UC; Receptos acquired by Celgene for ~$7.2B in 2015); founded Syrrx (acquired by Takeda 2005, yielded Nesina for T2D); contributed to Palynziq (BioMarin, approved 2018). Academic: tenured at Scripps, founded the GPCR Network / Joint Center for Structural Genomics. Started Structure (as ShouTi) in 2016–2018 with former students.
• Skin in the game / ownership: founder with significant equity; precise insider % n/a — not parsed from filings here. Institutional anchor is real — FMR LLC (Fidelity) held ~31.1M shares (~15%) as of 2025-12-31, a high-conviction crossover-quality holder. Casdin Capital trimmed 380k shares in Q4 2025 — a specialist nibbling profits after the spike, not a red flag.
• Capital-allocation history: disciplined for a clinical biotech — raised opportunistically into strength (IPO $166.7M Feb-2023; PIPE $281.5M Oct-2023; follow-on $512.7M Jun-2024; ATM $55.8M Sep-2025; follow-on $701.5M Dec-2025 immediately after the data pop — textbook "raise when you can, not when you must"). The $100M IP license shows willingness to monetize non-core assets non-dilutively. Deprioritizing ANPA-0073 on weak data is good discipline, not a stumble.
• Founder vs professional manager: founder/scientist archetype — exactly right for a structure-based-discovery platform at this stage. Added a professional spine in April 2026: Matthew Lang, J.D., as COO & General Counsel, the kind of operational hire you make heading into Phase 3 and a potential commercial build (or sale).
• Red flags on people: none material surfaced. The watch-item is execution risk of a first-time-at-scale commercial/Phase-3 organization against the most sophisticated competitor in pharma.

Lens 10 · Forensic Red Flags

For a pre-revenue biotech the forensic surface is dilution, going-concern, trial integrity, and SBC — not revenue recognition. Read against the financials:

• Revenue recognition: N/A — no product revenue. The only inflow is the $100M license fee; watch how it's recognized (upfront vs deferred) in future filings — in Q1-2026 it appears as a $100M "other receivable" collected into operating cash flow, which flatters Q1 operating cash flow to +$15.2M despite a $76.0M net loss. Do not read the positive operating cash flow as the company turning a corner — true cash burn ex-license is ~$76M net loss less ~$12.6M non-cash (SBC $11.6M + D&A/lease/accretion) ≈ $63M underlying quarterly burn.
• Burn trajectory: net loss $141.2M FY2025; $76.0M Q1-2026 vs $46.8M Q1-2025 (+62% YoY). Burn is accelerating into Phase 3 — expected, but means the "through end of 2028" runway assumes a spend ramp that, if it overshoots, shortens the runway.
• Liquidity / going-concern: $1,458.5M cash + short-term investments at 2026-03-31; no debt (total liabilities just $61.0M, almost all leases/payables). Management states runway through end of 2028, funding the Phase 3 registrational program but explicitly excluding pre-commercialization / commercial manufacturing. No going-concern qualification. This is one of the best-capitalized clinical obesity names — runway comfortably reaches multiple value-inflection catalysts.
• Stock-based comp: $11.6M in Q1-2026 (~13% of opex), up from $5.9M YoY. Rising but normal for a staffing-up biotech; dilution is the bigger story — share count went 171.9M (Dec-2024) → 213.2M (Mar-2026), ~+24% in five quarters from raises. The ATM was expanded to $400M with ~$341.5M still available — meaningful overhang of at-the-market dilution ahead.
• Trial-design / foreign-data integrity: the company runs initial studies outside the US and flags that FDA may not accept the foreign data — a real Phase-3/regulatory risk it discloses itself.
• Pipeline honesty: ANPA-0073 deprioritized after long-term GLP-toxicology studies showed it "was not suitable for selective weight loss" — disclosed cleanly; counts as candor, not concealment.

Regulatory findings:

• SEC Litigation Releases: 0 naming Structure Therapeutics (EDGAR EFTS, since 2021-06-17).
• SEC AAERs: 0.
• 10-K Item 3 (Legal Proceedings): no material litigation surfaced in the reviewed filing text (standard for a young clinical company; the patent estate is the asset, IP disputes are the forward risk).
• Non-SEC (FDA/FTC/DOJ) web check: no material enforcement actions found; the relevant FDA interactions are ordinary clinical/regulatory (End-of-Phase-2 meeting, foreign-data acceptance), not enforcement.
• Conclusion: No material regulatory or legal findings — verified via SEC EDGAR EFTS (LR, AAER), web search, and 10-K Item 3 as of 2026-06-18.

Add (Science & exclusivity — +clinical sub-section). Mechanism is validated (GLP-1 is the most de-risked target in metabolic disease; the question is competitive, not biological). Scientific-founder credibility is top-tier (Lens 9). IP estate proven monetizable ($100M license). LOE/patent-cliff timing for aleniglipron n/a — not parsed, but composition-of-matter coverage on a 2016-era small molecule plausibly runs into the early-to-mid 2030s — which, given a ~2030 launch, is the real concern: a thin post-launch exclusivity window behind orforglipron.

---

Phase D — Project & stress-test

Lens 11 · rNPV + Runway-to-Catalyst (replaces Forward Projection)

No EPS line for a pre-revenue name. The two questions that matter:

(1) Does runway reach the next value-inflection catalyst? — Yes, comfortably.

• Cash + ST investments $1,458.5M (2026-03-31); underlying burn ~$63M/qtr and rising; management-guided runway through end of 2028 including the Phase 3 start. Even on a conservative ramp to ~$90–110M/qtr as Phase 3 enrolls, the balance sheet clears the Q3 2026 Phase 3 initiation, the ADA dataset, the first ACCG-2671 human data, and well into the Phase 3 readout window. Plus a $341.5M untapped ATM as a buffer. Funding risk is low through the next two years; the dilution cost of staying funded is the real drag.

(2) Rough rNPV sketch of aleniglipron (the value driver) — all inputs ``, shown for transparency, not precision:

• Oral obesity TAM is enormous (tens of billions); assume aleniglipron, if approved ~2030, captures a modest #3–4 oral share → peak risk-unadjusted sales ~$2–4B.
• PoS to approval from Phase 3 start ~50–60% for a de-risked GLP-1 with positive Phase 2b.
• Apply PoS × a mid-teens % discount over ~4-yr launch lag → rNPV broadly consistent with today's ~$2.9B market cap. Translation: the current price already embeds a credible-but-not-dominant aleniglipron plus option value on amylin — it is neither obviously cheap nor obviously rich. The upside is a partnership/M&A premium or a best-in-class Phase 3 differentiating it from orforglipron; the downside is share-loss to an entrenched Foundayo + Wegovy-pill + Viking.

Brier forecast to log (NOT run in --watchlist breadth mode): GPCR aleniglipron Phase 3 (chronic weight management) initiates on or before 2026-12-31, p≈0.85 — and the more scoreable thesis binary: GPCR is acquired OR signs a major ex-US/global obesity partnership before 2027-12-31, p≈0.40. Not logged — breadth loop.

Lens 12 · Bull vs Bear

Bull case. Structure owns a genuinely best-in-class oral GLP-1 on efficacy — ACCESS II's 15–16% placebo-adjusted loss is the highest among oral GLP-1RAs at the 44-week timepoint and approaches injectable territory. The 2.5mg titration fix neutralized the tolerability knock (the one soft spot in the core data). It is fortress-funded ($1.46B, no debt, runway to end-2028) so it never has to raise from weakness. It has a second, first-in-class oral amylin shot (ACCG-2671) entering human data in 2026. And it is run by the structure-based-discovery founder with a multi-exit track record (Receptos/Zeposia, Syrrx/Takeda) — exactly the profile an acquirer pays up for. In a world where every large pharma needs an oral obesity asset, a clean, well-capitalized, best-oral-efficacy single-asset story is a prime M&A target — and Fidelity's ~15% anchor signals smart-money conviction.

Bear case (the 2–3 things that permanently impair it).

1. The race is already lost on time. Orforglipron (Foundayo) is FDA-approved (Apr 1, 2026); the Wegovy pill is approved; Viking's oral is entering Phase 3. Aleniglipron's Phase 3 only starts Q3 2026 → realistic launch ~2030. By then Lilly will have years of formulary lock-in, manufacturing scale, and combination follow-ons. A latecomer #4 oral GLP-1 with no differentiated mechanism faces structural share compression.
2. Efficacy edge is fragile and cross-trial. The 15–16% figures are exploratory ACCESS II / longer-timepoint numbers vs orforglipron's registrational 72-week 12.4% — comparing across trials/durations is exactly how Phase-2 darlings disappoint in Phase 3. The core ACCESS 11.3% with 10.4% discontinuation is the honest baseline, and it is not clearly better than an approved drug.
3. Dilution overhang + no pricing power. ~+24% shares in five quarters and $341.5M ATM still loaded; a single-asset, ~2030-launch story funds itself by issuing stock into every rally.

Pre-mortem (18 months out, thesis broke): It's late 2027. Aleniglipron Phase 3 read out roughly in line with — not better than — orforglipron, the cross-trial efficacy edge evaporated, and with Foundayo entrenched the Street re-rated GPCR as "a me-too oral #4 that needs to be acquired to matter," but no large pharma bid at a premium because they'd rather build internally. The ATM kept printing shares. Stock halved.

Is the multiple too high? There is no multiple — but the ~$2.9B cap already prices a credible aleniglipron; there is little margin of safety for a disappointing-but-not-failed Phase 3, which is the most likely adverse outcome (data fine, but not differentiated).

Contrarian view (what the market may be refusing to see): The market is anchored on aleniglipron-vs-orforglipron as a loss. The non-obvious value is the platform + amylin + IP-licensing engine — the $100M license proved Structure can spin cash out of its discovery estate independent of the lead asset, and ACCG-2671 as the most-advanced oral amylin could become the more valuable program if amylin proves the next leg of obesity. The real bet may not be "does aleniglipron beat Foundayo" but "is Structure the cheapest way to own oral small-molecule metabolic optionality that a pharma must eventually buy."

Lens 13 · Devil's Advocate (short-seller)

Dismantling the bull case:

• Where revenue is concentrated: there is none, and ~100% of the equity value rests on one Phase-3-pending asset into the teeth of an approved competitor. Single-asset binary risk, maximal.
• Why the moat is weaker than bulls think: the "oral small-molecule scalability" moat is shared by Lilly, Pfizer, Roche, Viking — it is a category advantage, not Structure's. Lilly has the same modality plus approval, scale, and a sales force.
• Most dangerous competitor bulls underestimate: not even orforglipron — it's Lilly itself iterating (next-gen oral, oral combos) and Novo's pill franchise, which can discount and bundle Structure out of formularies before it ever launches.
• Worst capital-allocation / incentive read: the loaded $341.5M ATM means management will dilute into strength indefinitely; the cross-trial efficacy framing in IR materials is promotional (selling exploratory long-timepoint numbers against a competitor's registrational number).
• Assumptions that must hold for today's price: (a) Phase 3 reproduces and differentiates the Phase-2 efficacy; (b) FDA accepts the program incl. ex-US data; (c) a partner/acquirer pays a premium; (d) oral obesity isn't commoditized by 2030. If growth/efficacy disappoints by 20–30% (i.e., Phase 3 lands at ~9–11% placebo-adjusted, in-line not best), the M&A premium evaporates and the stock likely halves toward a cash-plus-modest-option floor (cash alone is ~$1.46B ≈ ~$20/ADS-equiv ).
• Single scenario that permanently impairs: a Phase 3 safety signal (hepatic, GI, or the discontinuation rate reasserting at scale) on a mechanism where an approved, cleaner-profile competitor already exists — that doesn't just delay, it ends the asset's commercial case.

Lens 14 · Management Questions (ordered by information value)

1. Given orforglipron is approved and you start Phase 3 in Q3 2026, what is the realistic US launch year for aleniglipron, and what specifically differentiates it from Foundayo at that point — efficacy, tolerability, dosing, or price?
2. The Phase 3 starts at 2.5mg titration — what is the target therapeutic dose and the expected placebo-adjusted weight loss at 72 weeks, and how confident are you that core-ACCESS 11.3%/10.4%-discontinuation, not exploratory ACCESS II 16%, is the right base rate?
3. Is your strategic intent to commercialize independently or to partner/sell? What would make you choose one over the other?
4. Who paid the $100M upfront license, for what GLP-1 patent class, and what are the downstream milestone/royalty economics?
5. What is the expected quarterly burn through Phase 3 readout, and at what cash level do you tap the $341.5M ATM vs. a partnership?
6. On ACCG-2671: your own 10-K says semaglutide combination beat it in preclinical monotherapy — what is the standalone vs combination commercial thesis for the oral amylin, and what efficacy bar in the Q3 SAD/MAD would justify accelerating it?
7. How are you protecting against FDA non-acceptance of ex-US clinical data in the Phase 3 program?
8. What is the composition-of-matter patent expiry for aleniglipron, and how many years of exclusivity remain post a ~2030 launch?
9. What is the manufacturing cost-of-goods and capacity plan to supply a population-scale oral drug, and which CDMOs anchor it?
10. How do you think about cardiovascular / outcomes and indication-expansion trials (CKD, MASH, OSA) — are you resourced to run the label-expansion playbook Lilly/Novo are running?
11. What insider purchases have executives made since the Dec-2025 data, and how should investors read the Casdin trim?
12. With Viking's oral dual-agonist entering Phase 3, why is a single GLP-1 mechanism the right bet versus a GLP-1/GIP or GLP-1/amylin combination?
13. What would you need to see to deprioritize aleniglipron in favor of the amylin franchise, as you did with ANPA-0073?
14. What does the G&A ramp (+70% YoY) fund — is this a pre-commercial build, and does it presume independent launch?
15. If a large pharma offered to acquire Structure tomorrow, what value are you certain the market is not yet crediting?

---